Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Autor:
Megan Cole, Jesse Boumelha, Miriam Llorian Sopena, Miriam Molina-Arcas, Panos Anastasiou, Sareena Rana, Christopher I. Moore, Febe van Maldegem, Philip East, Julian Downward, Edurne Mugarza, Karishma Valand, Pablo Romero Clavijo, Rachel Ambler
The recent development and approval of KRASG12C inhibitors promises to change profoundly the clinical management of lung cancer patients harbouring KRASG12C mutations. However, early clinical data indicate that acquired drug resistance can frequently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebd4728b44a095dd96a3a4fd4745a56
https://doi.org/10.1101/2021.10.18.464819
https://doi.org/10.1101/2021.10.18.464819
BackgroundDurable treatments that benefit a wide pool of patients remain elusive for Non-small cell lung cancer (NSCLC). The success of immunotherapy in a subset of NSCLC patients highlights the potential contribution of immune response to anti-tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eedef86090d57667d0fd6c518116c048
https://doi.org/10.1101/2021.10.01.462824
https://doi.org/10.1101/2021.10.01.462824
Publikováno v:
PLoS Computational Biology, Vol 18, Iss 1, p e1009504 (2022)
PLoS Computational Biology
PLoS Computational Biology
Chimeric antigen receptor (CAR) T-cell therapy is potentially an effective targeted immunotherapy for glioblastoma, yet there is presently little known about the efficacy of CAR T-cell treatment when combined with the widely used anti-inflammatory an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7451b13ee8afaabd19854303d770f5d
https://doi.org/10.1101/2021.10.01.462697
https://doi.org/10.1101/2021.10.01.462697
Autor:
Tao Dao, Martin G. Klatt, Zita E.H. Aretz, Andrew W Daman, Christopher M. Bourne, Sung Soo Mun, Ron S. Gejman, Katsuyoshi Takata, Christian Steidl, David A. Scheinberg
Exploring the repertoire of peptides presented on major histocompatibility complexes (MHC) has been utilized to identify targets for immunotherapy in many hematological malignancies. However, such data have not been described systematically for diffu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71ab16e9eb30b0977f84351fc9a1d7cb
https://doi.org/10.1101/2021.09.01.458572
https://doi.org/10.1101/2021.09.01.458572
Autor:
Sam O. Kleeman, Breanna Demestichas, Nicholas Mourikis, Dominik Loiero, Miriam Ferrer, Sean Bankier, Yosef J.R.A. Riazat-Kesh, Hassal Lee, Dimitrios Chantzichristos, Claire Regan, Jonathan Preall, Sarthak Sinha, Nicole Rosin, Bryan Yipp, Luiz G.N. de Almeida, Jeff Biernaskie, Antoine Dufour, Pinkus Tober-Lau, Arno Ruusalepp, Johan L. M. Bjorkegren, Markus Ralser, Florian Kurth, Vadim Demechev, Todd Heywood, Qing Gao, Gudmundur Johannsson, Viktor H. Koelzer, Brian R. Walker, Hannah V. Meyer, Tobias Janowitz
The secreted protein Cystatin C (CyC) is a cysteine protease inhibitor of incompletely characterized biomedical function, used clinically for estimation of glomerular filtration rate. Plasma CyC is elevated in many patients, especially when they rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b15f807a2bceeb5faa7785099921576
https://doi.org/10.1101/2021.08.17.21261668
https://doi.org/10.1101/2021.08.17.21261668
Autor:
Hira Rizvi, Fromm G, Chad M. Vanderbilt, Nicholas McGranahan, Mohsen Abu-Akeel, Pedro Beltrao, Benjamin D. Greenbaum, Umesh Bhanot, Taha Merghoub, Jia Luo, Martin L. Miller, Caroline G. McCarthy, Andrew Chow, Adam J. Schoenfeld, Andrew J. Plodkowski, Schreiber Th, Hellmann, Danish Memon, Jayon Lihm, Jennifer L. Sauter, Dajia Ye, Andy J. Minn, Cailian Liu, Marta Łuksza
Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC treated with PD-(L)1 blockade to clinically charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f914f732ff2849d421a324b47269014b
https://doi.org/10.1101/2021.07.21.452854
https://doi.org/10.1101/2021.07.21.452854
Autor:
Dakota B. Poschel, Zhou G, Dafeng Yang, Priscilla S. Redd, David H. Munn, Alyssa D. Merting, Kebin Liu, Chunwan Lu, John D. Klement
The mechanism underlying tumor cell PD-L1 (tPD-L1) induction of immune suppression through T cell PD-1 is well-known, but the mechanism underlying tPD-L1 induction of immune suppression via an intermediate cell is incompletely understood. We report h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9022eef26a6dd03bc29f2009f2e4b02d
https://doi.org/10.1101/2021.06.18.449028
https://doi.org/10.1101/2021.06.18.449028
Autor:
Rachel Nakagawa, Yibing Zhang, Joyce V. Lee, Filomena Housley, Carole Baas, Daniel Van de Mark, Susan Samson, Laura J. van't Veer, Golzar Hemmati, Mehrdad Matloubian, Grace A. Hernandez, Laura J. Esserman, Juliane Winkler, Andrei Goga, Hope S. Rugo, Christina Yau
For many human cancers, including triple negative breast cancer (TNBC), a modest number of patients benefit from immune checkpoint inhibitors, and few experience cancer remission1. Expression of programed death-ligand 1 (PD-L1), tumor immune infiltra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96ef66abcc1f9601a37b22188d5d307c
https://doi.org/10.1101/2021.05.07.442684
https://doi.org/10.1101/2021.05.07.442684
Autor:
Simone Ragusa, Krisztian Homicsko, Francois Rivest, Devanjali Dutta, Nicolas Broguiere, Nathalie Brandenberg, Damien Saugy, Sylke Hohnel, Matthias P. Lutolf, Sylvie Rusakiewicz, L. Francisco Lorenzo-Martín, Lucie Tillard, George Coukos
Immunotherapy has shown promise as an approach to fight cancer by harnessing the immune system. However, due to the lack of biomarkers to guide treatment regimens and predict response rates, there is an unmet need for more robust ex vivo and in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6904e0ba640f51373e3011ba8934e2cd
https://doi.org/10.1101/2021.03.30.437679
https://doi.org/10.1101/2021.03.30.437679
Autor:
Liron D. Grossmann, Yasin Uzun, Darya Volgina, May M. Dong, Alba Rodriguez-Garcia, Jessica L. Dessau, Michael D. Hogarty, Chi V. Dang, John M. Maris, Kai Tan, Adam J. Wolpaw, Daniel J. Powell, Patricia Brafford
Immunotherapy has revolutionized cancer treatment, but many cancers are not impacted by currently available immunotherapeutic strategies. Here, we investigated inflammatory signaling pathways in neuroblastoma, a classically "cold" pediatric cancer. B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779c6cea88a927dbc12d0212d1f68398
https://doi.org/10.1101/2021.01.27.428523
https://doi.org/10.1101/2021.01.27.428523